

Ruth Tachezy

Kapitoly v monografiích

1. Saláková M, Šmahelová J, Hamšíková E, **Tachezy R.** „Laboratorní diagnostika lidských papilomavirů.“ Respirační papilomatóza, TOBIÁŠ Medicína hlavy a krku, ed. Viktor Chrobok 2022, pp116-125, ISBN 978-80-7311-207-3.
2. Šmahelová J, **Tachezy R.** „Lidské papilomaviry.“ Respirační papilomatóza, TOBIÁŠ Medicína hlavy a krku, ed. Viktor Chrobok 2022, pp60-63, ISBN 978-80-7311-207-3.
3. **Tachezy R,** Šmahelová J. „Úloha nízké rizikových lidských papilomavirů v patogenezi nádorů.“ Respirační papilomatóza, TOBIÁŠ Medicína hlavy a krku, ed. Viktor Chrobok 2022, pp64-69, ISBN 978-80-7311-207-3
4. Hamšíková E, **Tachezy R,** Němečková Š. „Profylaktické vakcíny proti lidským papilomavirům: prostředek primární prevence karcinomu děložního hrdla, eventuálně dalších nádorů spojených s infekcí HPV.“ Onkologická imunologie, Mladá fronta a.s., ed. E. Zavadová, 2015, pp93-107, ISBN 978-80-204-3756-3.
5. Van Ranst M, **Tachezy R,** Delius H, Burk RD. Classification of the human papillomaviruses based on their molecular evolutionary relationship. In: “Human papillomavirus infection in dermatovenereology”, eds. Von Krogh G. and Gross G., CRC Press, Inc., Florida, U.S.A., 1996.
6. Van Ranst M, **Tachezy R,** Burk RD. Human papillomaviruses: A neverending story? In: “Papillomavirus Reviews: Current Research on Papillomaviruses”, ed. Lacey C., Royal Society of Medicine Services Ltd., Leeds University Press, p. 1-20, 1996.

Původní práce a práce v recenzovaných sbornících – národních/mezinárodních s impakt faktorem

1. Kadleckova D, **Tachezy R,** Erban T, Deboutte W, Nunvar J, Salakova M, Matthijnssens J.
The Virome of Healthy Honey Bee Colonies: Ubiquitous Occurrence of Known and New Viruses in Bee Populations.
mSystems, 7, 3, 2022. (cited 1x) **IF2021=7.328**
2. Kliegr T, Jarkovsky J, Jirincova H, Kuchar J, Karel T, **Tachezy R.**
Role of population and test characteristics in antigen-based SARS-CoV-2 diagnosis, Czechia, August to November 2021.
Eurosurveillance, 27, 33, 2200070, 2022. (cited 0x) **IF2021=21.286**
3. Pokryvkova B, Grega M, Klozar J, N, Vecalek O, Nunvar J, **Tachezy R.**
PD1+CD8+ Cells Are an Independent Prognostic Marker in Patients with Head and Neck Cancer.
Biomedicines, 10, 11, 2794, 2022. (cited 0x) **IF2021=4.757**
4. Smahelova J, Hamsikova E, Ludvikova V, Vydrova J, Traboulsi J, Vecalek O, Lukes P, **Tachezy R.**
Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.

Ruth Tachezy

- JAMA Otolaryngology-Head and Neck Surgery, 148, 7, 654-661, 2022. (cited 0x) **IF2021=8.961**
5. Rob F, Hugo J, Salakova M, Smahelova J, Gkalpakiotis S, Bohac P, **Tachezy R**.
Prevalence of genital and oral human papillomavirus infection among psoriasis patients on biologic therapy.
Dermatologic Therapy, 35, 10, e15735, 2022. (cited 0x) **IF2021=3.858**
 6. Pokryvkova B, Smahelova J, Dalewska N, Grega M, Vencalek O, Smahel M, Nunvar J, Klozar J, **Tachezy R**.
ARG1 mRNA Level Is a promising Prognostic Marker in Head and Neck Squamous Cell Carcinomas.
Diagnostics, 11, 4, 628, 2021. (cited 3x) **IF2021=3.992**
 7. Malerova S, Hejtmankova A, Hamsikova E, Salakova M, Smahelova J, Klozar J, **Tachezy R**.
Prevalence and Risk Factors for Oral HPV in Healthy Population, in Central Europe.
Anticancer Res, 40, 3, 1597-1604, 2020. (cited 5x) **IF2021=2.435**
 8. Nunvar J, Pagacova L, Vojtechova Z, de Azevedo NTD, Smahelova J, Salakova M, **Tachezy R**.
Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.
Biomolecules, 11, 5, 764, 2021. (cited 2x) **IF2021=6.064**
 9. Kanwal M, Smahel M, Olsen M, Smahelova J, **Tachezy R**.
Aspartate β -hydroxylase as a target for cancer therapy.
Journal of Experimental & Clinical Cancer Research, 39, 1, 163, 2020. (cited 14x) **IF2021=12.658**
 10. Maléřová S, Kalfert D, Grega M, **Tachezy R**, Klozar J.
The significance of p16 protein expression in oral squamous cell carcinoma.
Epidemiologie Microbiologie Immunologie, 69, 2, 64-72, 2020. (cited 0x) **IF2021= 0.5**
 11. Pokryvková B, Salaková M, Smahelova J, Vojtechova Z, Novosadova V, **Tachezy R**.
Detailed characteristics of tonsillar tumors with extrachromosomal or integrated form of human papillomavirus.
Viruses, 12, 1, pii: E42, 2019. (cited 2x) **IF2021=5.818**
 12. Simonidesova S, Hamsikova E, Ludvikova V, Klozar J, Vencalek O, **Tachezy R**.
Prognostic value of post-treatment HPV-specific antibodies in patients with oropharyngeal tumours.
Journal of Surgical Oncology, 120, 2019. (cited 1x) **IF2021=2.885**
 13. Bozinovic K, Sabol I, Dediol I, Milutin Gasperov N, Vojtechova Z, **Tachezy R**, Grce M.
Genome wide miRNA profiling reinforces the importance of miR-9 in human papillomavirus associated oral and oropharyngeal head and neck cancer.
Scientific Reports, 9, 1, 2306, 2019. (cited 28x) **IF2021=4.997**
 14. Polakova I, Pelak O, Thürner D, Pokryvkova B, **Tachezy R**, Kalina T, Smahel M.
Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors.
Journal of Immunology Research, 2019:6705949, 2019. (cited 4x) **IF2021=4.493**
 15. Simonidesova S, Hamsikova E, Klozar J, **Tachezy R**.

Ruth Tachezy

- The prevalence of oral HPV infection in healthy populations: A systematic review with a focus on European populations.
Epidemiologie Mikrobiologie Imunologie, 67, 4, 175-183, 2018. (cited 4x) **IF2021=0.5**
16. Grzelak A, Polakova I, Smahelova J, Vackova J, Pekarcikova L, **Tachezy R**, Smahel M.
Experimental Combined Immunotherapy of Tumours with Major Histocompatibility Complex Class I Downregulation.
International Journal of Molecular Sciences, 19, 11, E3693, 2018. (cited 3x) **IF2021=6.208**
17. Hladikova K, Partlova S, Koucky V, Boucek J, Fonteneau JF, Zabrodsky M, **Tachezy R**, Grega M, Spisek R, Fialova A.
Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
Oral Oncology, 82, 75-82, 2018. (cited 13x) **IF2021=5.972**
18. Vojtechova Z, **Tachezy R**.
The Role of miRNAs in Virus-Mediated Oncogenesis.
International Journal of Molecular Sciences, 19, 4, E1217, 2018. (cited 35x) **IF2021=6.208**
19. Salakova M, Koslabova E, Grega M, Smahelova J, Klozar J, Vencalek O, **Tachezy R**.
Mucosal and skin HPV types in tumour-free tonsils and tonsillar tumours.
Neoplasma, 65, 2, 278-286, 2018. (cited 1x) **IF2021=3.409**
20. Vojtechova Z, Zavadil J, Klozar J, Grega M, **Tachezy R**.
Comparison of the miRNA expression profiles in fresh frozen and formalin-fixed paraffin-embedded tonsillar tumors.
PLoS One, 12, 6, e0179645, 2017. (cited 9x) **IF2021=3.752**
21. Rob F, **Tachezy R**, Pichlík T, Skapa P, Rob L, Hamsikova E, Smahelova J, Hercogova J.
Concordance of HPV-DNA in cervical dysplasia or genital warts in women and their monogamous long-term male partners.
Journal of Medical Virology, 89, 9, 1662-1670, 2017. (cited 3x) **IF2021=20.693**
22. Hamsikova E, Smahelova J, Ludvikova V, Salakova M, Rychla J, Skrenkova J, Rob L, **Tachezy R**.
The prevalence of HPV infections in HPV-vaccinated women from the general population.
APMIS, 125, 6, 585-595, 2017. (cited 4x) **IF2021=3.428**
23. Ragin C, Liu JC, Jones G, Shoyele O, Sowunmi B, Kennett R, Groen HJ, Gibbs D, Blackman E, Esan M, Brandwein MS, Devarajan K, Bussu F, Chernock R, Chien CY, Cohen MA, Samir EM, Mikio S, D'Souza G, Funchain P, Eng C, Gollin SM, Hong A, Jung YS, Krüger M, Lewis J Jr, Morbini P, Landolfo S, Rittà M, Straetmans J, Szarka K, **Tachezy R**, Worden FP, Nelson D, Gatherer S, Taioli E.
Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients.
Carcinogenesis, 38, 2, 218-229, 2017. (cited 21x) **IF2021= 4.741**
24. Rob F, **Tachezy R**, Pichlik T, Rob L, Kruzicova Z, Hamsikova E, Smahelova J, Hercogova J.

Ruth Tachezy

High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts - another reason for HPV vaccination of boys.

Dermatologic Therapy, 30, 2016, e12435. (cited 8x) **IF2021=3.858**

25. Smahelova J, Kastankova I, Machova-Polakova K, Klamova H, Zemanova K, **Tachezy R**, Hamsikova E, Smahel M.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia.

Oncology Reports, 37, 1, 547-554, 2017. (cited 3x) **IF2021=4.136**

26. Sabol I, Smahelova J, Klozar J, Mravak-Stipetic M, Gheit T, Tommasino M, Grce M, **Tachezy R**.

Beta-HPV types in patients with head and neck pathology and in healthy subjects.

Journal of Clinical Virology, 82, 159-165, 2016. (cited 15x) **IF2021=14.481**

27. Vojtechova Z, Sabol I, Salakova M, Smahelova J, Zavadil J, Turek L, Grega M, Klozar J, Prochazka B, **Tachezy R**.

Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones.

BMC Cancer, 16, 382, 2016. (cited 28x) **IF2021=4.638**

28. Jelen MM, Chen Z, Kocjan BJ, Hosnjak L, Burt FJ, Chan PK, Chouhy D, Combrinck CE, Estrade C, Fiander A, Garland SM, Giri AA, Gonzalez JV, Gröning A, Hibbitts S, Luk TN, Marinic K, Matsukura T, Neumann A, Oštrbenk A, Picconi MA, Sagadin M, Sahli R, Seedat RY, Seme K, Severini A, Sinchi JL, Smahelova J, Tabrizi SN, **Tachezy R**, TohmeFaybush S, Uloza V, Uloziene I, Wong YW, Zidovec Lepej S, Burk RD, Poljak M.

Global genomic diversity of human papillomavirus type 11 (HPV11) based on 433 isolates and 78 complete genome sequences.

Journal of Virology, 90, 11, 5503-5513, 2016. (cited 16x) **IF2021= 6.549**

29. VojtechovaZ, Sabol I, Salakova M, Turek L, Grega M, Smahelova J, Vencalek O, Lukesova E, Klozar J, **Tachezy R**.

Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis.

International Journal of Cancer, 138, 2, 2016. (cited 49x) **IF2021=7.316**

30. Salakova M, Koslabova E, Vojtechova Z, **Tachezy R**, Sroller V.

Detection of human polyomaviruses MCPyV, HPyV6, and HPyV7 in malignant and non-malignant tonsillar tissues.

Journal of Medical Virology, 88, 4, 695-702, 2016. (cited 35x) **IF2021=20.693**

31. Rob L, **Tachezy R**, Robova H.

Cervical cancer: what is the optimal age for routine testing?

Future Oncology, 11, 8, 1137-1140, 2015. (cited 0x) **IF2021=3.674**

32. Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, Fucikova J, Truxova I, **Tachezy R**, Spisek R, Fialova A.

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.

OncoImmunology, 4, 1, 2015, e965570. (cited 142x) **IF2021= 7.723**

33. Sijmons S, Thys K, MbongNgwese M, Van Damme E, Dvorak J, Van LoockM, Li G, **Tachezy R**, Busson L, Aerssens J, Van Ranst M, Maes P.

Ruth Tachezy

High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.
Journal of Virology, 89, 15, 7673-7695, 2015. (cited 95x) **IF2021=6.549**

34. Klozar R, **Tachezy R.**

What are the implications of human papillomavirus status in oropharyngeal tumors for clinical practice?

Current Opinion in Otolaryngology & Head Neck Surgery, 22, 2, 90-94, 2014. (cited 7x) **IF2021=1.814**

35. Jelen MM, Chen Z, Kocjan BJ, Burt FJ, Chan PK, Chouhy D, Combrinck CE, Coutlee F, Estrade C, Ferenczy A, Fiander A, Franco EL, Garland SM, Giri AA, Gonzalez JV, Gröning A, Heidrich K, Hibbitts S, Hosnjak L, Luk TN, Marinic K, Matsukura T, Neumann A, Ostrbenk A, Picconi MA, Richardson H, Sagadin M, Sahli R, Seedat RY, Seme K, Severini A, Sinchi JL, Smahelova J, Tabrizi SN, **Tachezy R**, Tohme S, Uloza V, Vitkauskienė A, Wong YW, Zidovec Lepej S, Burk RD, Poljak M.

Global genomic diversity of human papillomavirus 6 based on 724 isolates and 190 complete genome sequences.

Journal of Virology, 88, 13, 7307-7316, 2014. (cited 24x) **IF2021=6.549**

36. Lukesova E, Boucek J, Rotnaglova E, Salakova M, Koslabova E, Grega M, Eckschlagner T, Rihova B, Prochazka B, Klozar J, **Tachezy R.**

High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas.

Biomed Research International, 2014, 2014, 303929. (cited 34x) **IF2021=3.246**

37. **Tachezy R**, Smahelova J, Kaspírková J, Salakova M.

Human papillomavirus Type-Specific Prevalence in the Cervical Cancer Screening Population of Czech Women.

Plos One, 8, 11, 2013, e79156. (cited 27x) **IF2021=3.752**

38. Koslabova E, Hamsikova E, Salakova M, Klozar J, Foltynova E, Salkova E, Rotnaglova E, Ludvikova V, **Tachezy R.**

Markers of HPV infection and survival in patients with head and neck tumors.

International Journal of Cancer, 133, 8, 1832-9, 2013. (cited 54x) **IF2021=7.316**

39. Klozar J, Koslabova E, Kratochvíl V, Salakova M, **Tachezy R.**

Nodal status is not a prognostic factor in patients with HPV-positive oral/oropharyngeal tumors.

Journal of Surgical Oncology, 107, 6, 625-633, 2013. (cited 48x) **IF2021=2.885**

40. **Tachezy R**, Hrbáček J, Hrbáček J, Salakova M, Smahelova J, Ludvikova V, Svec A, Urban M, Hamsikova E.

HPV persistence and its oncogenic role in prostate tumors.

Journal of Medical Virology, 84, 10, 1636-1645, 2012. (cited 18x) **IF2021=20.693**

41. Hamsikova E, Ludvikova V, Stasikova J, **Tachezy R.**

Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic.

Sexually Transmitted Infections, 89, 2, 133-137, 2013. (cited 13x) **IF2021=4.199**

42. Fik Z, Valach J, Chovanec M, Mazanek J, Kodet R, Kodet O, **Tachezy R**, Foltynova E, Andre S, Kaltner H, Gabius HJ, Smetana K Jr.

Loss of adhesion/growth-regulatory galectin-9 from squamous cell epithelium in head and neck carcinomas.

Ruth Tachezy

Journal of Oral Pathology & Medicine 42, 2, 166-173, 2013. (cited 14x)

IF2021=3.539

43. Hrbacek J, Urban M, Hamsikova E, **Tachezy R**, Heracek J.
Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review.
Urologic Oncology-Seminars and Original Investigations, 31, 7, 951-965. (cited 18x)
IF2021=2.954
44. Petrackova M, **Tachezy R**, Vonka V.
Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) I. Derivation, genetic stability, oncogenicity and immunogenicity.
International Journal of Oncology, 40, 5, 1668-1676, 2012. (cited 3x) **IF2021=5.884**
45. **Tachezy R**, Smahelova J, Salakova M, Arbyn M, Rob L, Skapa P, Jirasek P, Hamsikova E.
Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV.
PLoS One, 6, 7, 2011, e21913. (cited 18x) **IF2021=3.752**
46. Hrbacek J, Urban M, Hamsikova E, **Tachezy R**, Eis V, Brabec M, Heracek J.
Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study.
BMC Cancer, 11, 53, 2011. (cited 35x) **IF2021=4.638**
47. Rotnaglova E, **Tachezy R**, Salakova M, Prochazka B, Koslabova E, Vesela E, Ludvikova V, Hamsikova E, Klozar J.
HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers.
International Journal of Cancer, 129, 1, 101-110, 2011. (cited 61x) **IF2021=7.316**
48. Anttila A, Ronco G; Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE).
Description of the national situation of cervical cancer screening in the member states of the European Union.
European Journal of Cancer, 45, 15, 2685-2708, 2009. (cited 81x) **IF2021=10.002**
49. Lucansky V, Sobotkova E, **Tachezy R**, Duskova M, Vonka V.
DNA vaccination against bcr-abl-positive cells in mice.
International Journal of Oncology, 35, 4, 941-951, 2009. (cited 13x) **IF2021=5.884**
50. Nicula FA, Anttila A, Neamtiu L, Zakelj MP, **Tachezy R**, Chil A, Grce M, Kesić V.
Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union
European Journal of Cancer, 45, 15, 2679-2684, 2009. (cited 50x) **IF2021=10.002**
51. Salakova M, Nemecek V, **Tachezy R**.
TTV and HPV co-infection in cervical smears of patients with cervical lesions.
BMC Infectious Diseases, 9, 118, 2009. (cited 11x) **IF2021=3.669**
52. Sobotkova E, Duskova M, **Tachezy R**, Petrackova M, Vonka V.
Combined chemo - and immunotherapy of tumors induced in mice by bcr-abl-transformed cells.
Oncology Reports, 21, 3, 793-799, 2009. (cited 6x) **IF2021=4.136**

Ruth Tachezy

53. **Tachezy R**, Klozar J, Rubenstein L, Smith E, Salakova M, Smahelova J, Ludvikova V, Rotnaglova E, Kodet R, Hamsikova E.
Demographic and risk factors in patients with head and neck tumors.
Journal of Medical Virology, 81, 5, 878-887, 2009. (cited 70x) **IF2021=20.693**
54. Klug SJ, Rensing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, DelMistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y, Pegoraro R, Pillai MR, Ranzani G, Rezza G, Rosenthal AN, Roychoudhury S, Saranath D, Schmitt VM, Sengupta S, Settheetham-Ishida W, Shirasawa H, Snijders PJ, Stoler MH, Suarez-Rincon AE, Szarka K, **Tachezy R**, Ueda M, van der Zee AG, von KnebelDoeberitz M, Wu MT, Yamashita T, Zehbe I, Blettner M.
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies.
Lancet Oncology, 10, 8, 772-784, 2009. (cited 123x) **IF2021=54.433**
55. **Tachezy R**, Davies P, Arbyn M, Rob L, Lazdane G, Petrenko J, Hamsikova E, Bekova A, Klozar J, Duskova J.
Consensus recommendations for cervical cancer prevention in the Czech Republic: a report of the International Conference on Human Papillomavirus in Human Pathology (Prague, 1-3 May 2008).
Journal of Medical Screening, 15, 4, 207-210, 2008. (cited 8x) **IF2021=1.687**
56. Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, Gasperov NM, Grce M, **Tachezy R**.
Evaluation of different techniques for identification of humanpapillomavirus types of low prevalence.
Journal of Clinical Microbiology, 46, 5, 1606-1613, 2008. (cited 32x) **IF2021=11.677**
57. Klozar J, Kratochvil V, Salakova M, Smahelova J, Vesela E, Hamsikova E, Betka J, **Tachezy R**.
HPV status and regional metastasis in the prognosisof oral and oropharyngeal cancer.
European Archives of Oto-Rhino-Laryngology, 265, S1, S75-S82, 2008. (cited 73x) **IF2021=3.236**
58. **Tachezy R**, Jirasek T, Salakova M, Ludvikova V, Kubecova M, Horak L, Mandys V, Hamsikova E.
Human papillomavirus infection and tumours of the anal canal: correlation of histology, PCR detection in paraffin sections and serology.
APMIS, 115, 3, 195-203, 2007. (cited 23x) **IF2021=3.428**
59. Skapa P, Zamecnik J, Hamsikova E, Salakova M, Smahelova J, Jandova K, Robova H, Rob L, **Tachezy R**.
Human papillomavirus (HPV) profiles of vulvar lesions. Possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination.
American Journal of Surgical Pathology, 31, 12, 1834-1843, 2007. (cited 44x) **IF2021=6.298**
60. Lacina L, Dvorankova B, Smetana K Jr, Chovanec M, Plzak J, **Tachezy R**, Kideryova L, Kucerova L, Cada Z, Boucek J, Kodet R, Andre S, Gabius HJ.
Marker profiling of normal keratinocytes identifies the stroma from squamous cell carcinoma of the oral cavity as a modulatory microenvironment in co-culture.

Ruth Tachezy

International Journal of Radiation Biology, 83, 11-12, 837-848, 2007. (cited 34x)
IF2021=3.352

61. **Tachezy R**, Smahelová J.
Quality assurance of human papillomavirus testing.
Collegium Antropologicum, 31 Suppl 2, 61-65, 2007. (cited 6x) **IF2021=0.609**
62. **Tachezy R**, Rob L.
Cervical cancer screening in the Czech Republic.
Collegium Antropologicum, 31, suppl 2, 27-29, 2007. (cited 6x) **IF2021=0.609**
63. Rector A, Lemey P, **Tachezy R**, Mostmans S, Ghim SJ, Van Doorslaer K, Roelke M, Bush M, Montali RJ, Joslin J, Burk RD, Jenson AB, Sundberg JP, Shapiro B, Van Ranst M.
Ancient papillomavirus-host co-speciation in Felidae.
Genome Biology, 8, 4, R57, 2007. (cited 124x) **IF2021=18.01**
64. **Tachezy R**, Mikysková I, Ludviková V, Rob L, Kucera T, Slavik V, Bekova A, Robová H, Pluta M, Hamsikova E.
Longitudinal study of patients aftersurgical treatment for cervical lesions: HPV DNA detection and prevalence of HPV-specific antibodies.
European Journal of Clinical Microbiology & Infectious Diseases, 25, 8, 492-500, 2006. (cited 15x) **IF2021=5.103**
65. Smahel M, Smahelova J, Tejklova P, **Tachezy R**, Jelinek F.
Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras.
Oncology Reports, 14, 6, 1665-1674, 2005. (cited 1x) **IF2021=4.136**
66. Smahel M, Smahelova J, Tejklova P, **Tachezy R**, Marinov I.
Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein.
International Journal of Oncology, 27, 3, 731-742, 2005. (cited 5x) **IF2021=5.884**
67. **Tachezy R**, Klozar J, Salakova M, Smith E, Turek L, Betka J, Kodet R, Hamsikova E.
HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic.
Oral Diseases, 11, 3, 181-185, 2005. (cited 46x) **IF2021=4.068**
68. Rector A, **Tachezy R**, Van Doorslaer K, MacNamara T, Burk RD, Sundberg JP, Van Ranst M.
Isolation and cloning of a papillomavirus from a North American porcupine by using multiply primed rolling-circle amplification: the Erethizontorsatum papillomavirus type 1.
Virology, 331, 2, 449-456, 2005. (cited 37x) **IF2021=3.513**
69. Jelinek F, **Tachezy R**.
Cutaneous papillomatosis in cattle.
Journal of Comparative Pathology, 132, 1, 70-81, 2005. (cited 45x) **IF2021=1.083**
70. Salakova M, Nemecek V, Konig J, **Tachezy R**.
Age-specific prevalence, transmission and phylogeny of TT virus in the Czech Republic.
BMC Infectious Diseases, 4, 1, 56, 2004. (cited 21x) **IF2021=3.669**
71. Rector A, **Tachezy R**, Van Ranst M.
A sequence-independent strategy for detection and cloning of circular DNA virus genomes by using multiply primed rolling-circle amplification.

Ruth Tachezy

- Journal of Virology, 78, 10, 4993-4998, 2004. (cited 138x) **IF2021=6.549**
72. Svec A, Mikyskova I, Hes O, **Tachezy R**.
Human papillomavirus infection of the epididymis and ductus deferens: an evaluation by nested polymerase chain reaction.
Archives of Pathology & Laboratory Medicine, 127, 11, 1471-1474, 2003. (cited 19x) **IF2021=5.686**
73. **Tachezy R**, Salakova M, Hamsikova E, Kanka J, Havrankova A, Vonka V.
Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions.
Sexually Transmitted Infections, 79, 3, 191-196, 2003. (cited 6x) **IF2021=4.199**
74. **Tachezy R**, Dusan G, Rector A, Jenson AB, Sundberg JP, Van Ranst M.
Cloning and genomic characterization of Felis domesticus papillomavirus type 1.
Virology, 301, 2, 313-321, 2002. (cited 57x) **IF2021=3.513**
75. **Tachezy R**, Rector A, Havelkova M, Wollants E, Fiten P, Opdenakker G, Jenson B, Sundberg J, Van Ranst M.
Avian papillomaviruses: the parrot Psittacus erithacus papillomavirus (PePV) genome has a unique organization of the early protein region and is phylogenetically related to the chaffinch papillomavirus.
BMC Microbiology, 2, 19, 2002. (cited 55x) **IF2021=4.465**
76. Tachezy J, **Tachezy R**, Hampl V, Sedinova M, Vanacova S, Vrlík M, Van Ranst M, Flegr J, Kulda J.
Cattle pathogen tritrichomonas foetus (Riedmuller, 1928) and pig commensal Tritrichomonas suis (Gruby&Delafond, 1843) belong to the same species.
Journal of Eukaryotic Microbiology, 49, 2, 154-163, 2002. (cited 76x) **IF2021=3.88**
77. Zehbe I, **Tachezy R**, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M.
Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes.
International Journal of Cancer, 94, 5, 711-716, 2001. (cited 98x) **IF2021=7.316**
78. Hamsikova E, Ludvikova V, **Tachezy R**, Kovarik J, Brouskova L, Vonka V.
Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpesviruses in patients with invasive cervical carcinoma.
International Journal of Cancer, 86, 3, 351-355, 2000. (cited 17x) **IF2021=7.316**
79. **Tachezy R**, Mikyskova I, Salakova M, Van Ranst M.
Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism.
Human Genetics, 105, 6, 564-566, 1999. (cited 36x) **IF2021=5.881**
80. Svec A, Urban M, Mikyskova I, **Tachezy R**.
Human papillomavirus in squamous metaplastic epithelium with dysplasia of the epididymis detected by PCR method.
American Journal of Surgical Pathology, 23, 11, 1437-1438, 1999. (cited 2x) **IF2021=6.298**
81. **Tachezy R**, Hamsikova E, Hajek T, Mikyskova I, Smahel M, Van Ranst M, Kanka J, Havrankova A, Rob L, Guttner V, Slavik V, Anton M, Kratochvil B, Kotrsova L, Vonka V.

Ruth Tachezy

- Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles.
Journal of Medical Virology, 58, 4, 378-386, 1999. (cited 33x) **IF2021=20.693**
82. Wadler S, Burk RD, Neuberger D, Rameau R, Runowicz CD, Goldberg G, McGill F, **Tachezy R**, Comis R, Edmonson J, Wiernik P.
Lack of efficacy of interferon-alpha therapy in recurrent, advanced cervical cancer.
Journal of Interferon and Cytokine Research, 15, 12, 1011-1016, 1995. (cited 13x) **IF2021=3.657**
83. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, **Tachezy R**, Lewis R, Romney S.
Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.
Journal of the National Cancer Institute, 87, 18, 1365-1371, 1995. (cited 591x) **IF2021=11.816**
84. **Tachezy R**, Van Ranst MA, Cruz Y, Burk RD.
Analysis of short novel human papillomavirus sequences.
Biochemical and Biophysical Research Communications, 204, 2, 820-827, 1994. (cited 42x) **IF2021=3.322**
85. Tan CH, **Tachezy R**, Van Ranst M, Chan SY, Bernard HU, Burk RD.
The Mastomys natalensis papillomavirus: nucleotide sequence, genome organization, and phylogenetic relation ship of a rodent papillomavirus involved in tumorigenesis of cutaneous epithelia.
Virology, 198, 2, 534-541, 1994. (cited 44x) **IF2021=3.513**
86. **Tachezy R**, Hamsikova E, Valvoda J, Van Ranst M, Betka J, Burk RD, Vonka V.
Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: correlation between Southern blot hybridization, polymerase chain reaction, and serology.
Journal of Medical Virology, 42, 1, 52-59, 1994. (cited 14x) **IF2021=20.693**
87. Van Ranst M, **Tachezy R**, Pruss J, Burk RD.
Primary structure of the E6 protein of Micromys minutus papillomavirus and Mastomys natalensis papillomavirus.
Nucleic Acids Research, 20, 11, 2889, 1992. (cited 8x) **IF2021=19.16**

Přehledné články a články v recenzovaných, neimpaktovaných časopisech a sbornících:

1. **Tachezy R**, Šmahelová J.
Proč vakcinovat chlapce?
Pediatrie pro praxi, 22, 4, 263-267, 2021.
2. Bouchilloux S, Fer F, Lemée F, Barradeau S, Dvorak V, Kubickova S, Ventruba P, **Tachezy R**, Trnková M, Janda P, Abscheidt J, Annibal E, El Mhali D, Garcia F, Kech M, Pilger G, Bensimon A, Mahé F.
Correlation between integration of high-risk HPV genome into human DNA detected by molecular combing and the severity of cervical lesions: first results of the EXPL-HPV-002 study.
Česká Gynekologie, 84, 2, 84-92, 2019.
3. Šmahelová J, Hamšíková E, **Tachezy R**.
Nové možnosti ochrany proti infekcím vyvolaným lidskými papilomaviry.

Ruth Tachezy

- Urologie pro praxi, 18, 2, 81-84, 2017.
4. Hamšíková E, Šmahelová J, Ludvíková V, Saláková M, Rychlá J, Skřenková J, Rob L, **Tachezy R**.
Očkování žen proti lidským papillomavirům: výsledky studie v České republice (vstupní data).
Praktická gynekologie, 18, 4, 179-183, 2014.
 5. Škapa P, Pichlík T, Pluta M, Halaška M, Robová H, Rob L, **Tachezy R**, Zámečník J.
Klasifikace vulvárních prekanceróz pohledem patologa.
Aktuální gynekologie a porodnictví, 6, 26-32, 2014.
 6. **Tachezy R**, Šmahel M.
Imunoterapie onemocnění vyvolaných infekcí lidskými papilomaviry.
Acta medicae, 4, 61-63, 2014.
 7. **Tachezy R**, Kuklová I.
Dermatovenerologické projevy infekcí vyvolaných lidskými papilomaviry.
Referátový výběr z dermatovenerologie, 7, 26-33, 2014.
 8. Maver PJ, Seme K, Korać T, Dimitrov G, Döbrössy L, Engele L, Iljazović E, Kesić V, Kostova P, Laušević D, Maurina A, Nicula FA, Panayotova Y, Primic Žakelj M, RepšeFokter A, Romejko-Wolniewicz E, Smailytė G, Şuteu O, Świdarska-Kiec J, **Tachezy R**, Valerianova Z, Veerus P, Vīberga I, Znaor A, Zubor P, Poljak M.
Cervical cancer screening practices in central and eastern Europe in 2012.
Acta Dermatovenereol APA, 22, 1, 7-19, 2013.
 9. **Tachezy R**, Šmahelová J.
Diagnostika lidských papilomavirů a její klinické využití.
Česká dermatovenerologie, 2, 4, 264, 2012.
 10. Hrbáček J, Urban M, Eis V, Hamšíková E, **Tachezy R**, Brabec M, Heráček J.
Infekční onemocnění urogenitálního traktu v anamnéze nemají vliv na biologické chování a prognózu karcinomu prostaty.
Česká urologie, 15, 3, 172-80, 2011.
 11. Dubová J, Vydrová J, Bendová O, **Tachezy R**, Hamšíková E, Traboulsi J.
Výsledky vakcinace proti HPV u pacientů s rekurentní papillomatózou hrtanu.
Postgraduální medicína, 13, 921, 2011.
 12. Šmahelová J., **Tachezy R**.
Závěrečné vyhodnocení EHK 534 - Detekce papillomavirů.
<http://www.papillomavirus.cz/aktuality/www-ehk534-final.pdf>, 2011.
 13. Hrbáček J, Heráček J, Eis V, Hamšíková E, **Tachezy R**, Urban M.
Incidence, diagnostika a léčba karcinomu prostaty u HIV pozitivních pacientů.
Česká urologie, 14, 1, 16-23, 2010.
 14. Hrbáček J, Konopásek P, Eis V, Hamšíková E, **Tachezy R**, Pokorný J, El-Balouly K, Urban M, Heráček J.
Urologické komplikace HIV/AIDS.
Časopis lékařů českých, 149, 3, 115-119, 2010.
 15. Rotnáglová E, **Tachezy R**, Saláková M, Košťabová E, Šmahelová J, Hamšíková E, Ludvíková V, Klozar J.
Vztah lidských papillomavirů a etiologie karcinomů patrových mandlí.
Otorinolaryngologie a Foniatrie (Prague), 59, 1, 32-7, 2010.
 16. Klozar J, **Tachezy R**, Rotnáglová E, Košťabová E, Saláková M, Hamšíková E.

Ruth Tachezy

- Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects.
Wiener Medizinische Wochenschrift, 160, 11-12, 305-309, 2010.
17. Driák D, Dyrhonová M, **Tachezy R**.
Vakcinace proti lidským papilomavirům a její kontroverze – I.
Gynekologie, 4, 128, 2009.
18. Driák D, Dyrhonová M, **Tachezy R**.
Vakcinace proti lidským papilomavirům a její kontroverze – I.
Gynekologie, 5, 180, 2009.
19. Driák D, Dyrhonová M, **Tachezy R**.
Vakcinace proti lidským papilomavirům a její kontroverze – I.
Gynekologie, 6, 214, 2009.
20. **Tachezy R**, Hamšíková E, Šmahelová J.
Cervical Cancer Screening in the Czech Republic.
Central European Journal of Public Health, 16, S31, 2008.
21. **Tachezy R**.
Epidemiologie papillomavirové infekce.
Antibiotiká a rezistencija, 7, 1, 6-9, 2008.
22. **Tachezy R**.
Detekce lidských papillomavirů a její klinické využití.
Antibiotiká a rezistencija, 7, 1, 25-29, 2008.
23. Klozar J, Zábrodský, Mudrová E, Hamšíková E, Saláková M, Šmahelová J, **Tachezy R**.
The role of HPV as a risk and prognostic factor in head and neck squamous cell carcinoma.
Central European Journal of Public Health, 16, S40, 2008.
24. Mudrová E, **Tachezy R**, Hamšíková E, Saláková M, Šmahelová J, Klozar J.
HPV pozitivní karcinom tonzily u pacientky s negativní kuřáckou a alkoholickou anamnézou.
Lékařské listy, 5, 33, 2008.
25. Hamšíková E, Ludvíková V, **Tachezy R**.
Antibodies of HPV capsids in sexual workers and controls in the Czech Republic.
Central European Journal of Public Health, 16, S51, 2008.
26. **Tachezy R**, Šmahelová J, Saláková M, Rob L, Škapa P, Klozar J, Jirásek T, Urban M, Hamšíková E.
Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked with HPV.
Central European Journal of Public Health, 16, S53, 2008.
27. Škapa P, Zámečník J, Hamšíková E, Saláková M, Šmahelová J, Jandová K, Robová H, Rob L, **Tachezy R**.
Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination.
Central European Journal of Public Health, 16, S58, 2008.
28. Mudrová E, Klozar J, Saláková M, Šmahelová J, **Tachezy R**.
Trends in epidemiology of head and neck cancer in the Czech population.
Central European Journal of Public Health, 16, S59, 2008.

Ruth Tachezy

29. **Tachezy R**, Šmahelová J, Ludvíková V, Saláková M, Hamšíková E.
HPV type distribution and seroprevalence of HPV-specific antibodies in vaccinated women in the Czech Republic.
Central European Journal of Public Health, 16, S60, 2008.
30. Hamšíková E, **Tachezy R**.
Infekce HPV – epidemiologické a klinické souvislosti.
Farmakoterapie Review, 4, 2007.
31. **Tachezy R.**, Rob L.
Skrínink pro prevenci karcinomu děložního hrdla v České republice.
Časopis lékařů českých, 12, 146, 938-944, 2007.
32. Robová H, Rob L, Pluta M, Kačírek J, Slavík V, Škapa P, Hamšíková E, **Tachezy R**.
Progression and regression low grade intraepithelial squamous lesions in context of positivity of high risk human papillomavirus.
Česká gynekologie, 72, 5, 347-350, 2007.
33. **Tachezy R**.
Dermatovenerologické projevy infekcí vyvolaných papillomaviry.
Lékařské listy, 16, 20–2, 2006.
34. **Tachezy R**.
Epidemiologie genitální papillomavirové infekce ve světě a ČR.
Moderní gynekologie, supplementum, 15, 4, 589-594, 2006.
35. **Tachezy R**, Hamšíková E.
Lidské papillomaviry v patogenezi neoplázií děložního čípku.
Moderní gynekologie a porodnictví, 12, 4, 2003.
36. **Tachezy R**.
Vakcinace proti HPV. Dospějeme jednou k eradikaci karcinomu děložního hrdla?
[komentář] Gynekologie po promoci, IV, 26-32, 2004.
37. **Tachezy R**.
Papillomaviry - věrní průvodci lidstva.
Živa, 4, 146-149, 2004.
38. Klozar, J., Klimák, P., Kodet, R., Saláková, M., Šmahelová, J., Hamšíková, E., **Tachezy, R**.
HPV a riziko orálního a orofaryngeálního karcinomu.
Otorinolaryngologie a foniatrie, 53,60-64, 2004.
39. **Tachezy R**, Hamšíková E.
Prekancerózy děložního hrdla. Lidské papillomaviry v patogenezi neoplázií čípku.
Moderní gynekologie a porodnictví, 12, 631-5, 2003.
40. Havránková A, Rychterová V, **Tachezy R**.
Vulvární intraepiteliální neoplázie.
Moderní gynekologie a porodnictví, 9, 425-430, 2000.
41. **Tachezy R**, Hamšíková E, Roubalová K, Suchánková A.
Virové infekce genitálu.
Moderní gynekologie a porodnictví, 9, 409–24, 2000.
42. **Tachezy R**.
Využití analýzy genomu pro taxonomii virů a studium jejich evoluce.
Remedia - Klinická Mikrobiologie, 2, 319-325, 1998.
43. **Tachezy R**.
Molekulární diagnostika a molekulární epidemiologie papillomavirů.

Úplná strukturovaná bibliografie pro habilitační a jmenovací řízení

Ruth Tachezy

- Remedia - Klinická Mikrobiologie, 7, 219-225, 1997.
44. Van Ranst MA, **Tachezy R**, Burk RD.
Human papillomavirus nucleotide sequences: What's in stock?
Papillomavirus Report, 5, 3, 65-75, 1994.
45. Valvoda, J., **Tachezy, R.**, Hamšíková, E., Betka, J., Klozar, J.
Průkaz lidských papillomavirů (HPV) a HPV specifických protilátek u pacientů s recidivující laryngeální papilomatózou.
Otorinolaryngology, 43, 184-189, 1994.
46. Van Ranst M, **Tachezy R**, Delius H, Burk RD.
Taxonomy of the human papillomaviruses.
Papillomavirus Report, 4, 61-65, 1993.

Různé závažné práce (např. recenze v odborných časopisech, dobrozdání, expertizy, encyklopedie, slovníky, příručky, překlady atd.)

Recenzní činnost pro mezinárodní vědecké časopisy

Journal of Medical Virology, Acta Veterinaria, Acta Virologica, BMC Oral Health, BMC Gastroenterology, BMC Cancer, BMC Urology, Clinical Chemistry and Laboratory Medicine, Clinical Infectious Diseases, Clinical Investigation, Collegium Antropologicum, Cytopathology, European Archives of Oto-Rhino-Laryngology and Head & Neck, Expert Review of Molecular Diagnostics, Sexually Transmitted Infections, International Journal of Cancer, Viral Immunology, Neoplasma, European Journal of Microbiology and Immunology, Central European Journal of Public Health, Future Medicine, Molecular Cancer, Cancer Letters, Journal of General Virology, Diagnostic Microbiology and Infectious Disease, European Journal of Clinical Microbiology & Infectious Diseases, Expert Review of Anti-infective Therapy, Future Virology, The International Journal of Biological Markers, Plos One, International Journal of Infectious Diseases and Epidemiology, BioMed Research International, Klinická onkologie, Vakcinologie, Epidemiologie, mikrobiologie, imunologie, Journal of Cellular and Molecular Medicine, Journal of Oral Pathology and Medicine, Scientific Reports, Genes, Journal of Clinical Medicine, Pathogens

Recenzent pro grantové agentury a další

Recenzent diplomových, disertačních, a atestačních prací, recenzent grantových projektů pro agentury GAČR ČR, IGA MZ ČR, AZV, Belgian Foundation against Cancer (Belgie), National Science Centre (Poland), The Agency for Health Quality and Assessment of Catalonia (AHQAC) (Španělsko)

Konferenční sborník

Ruth Tachezy: Central European Journal of Public Health, Vol 16 April 2008 Supplement.

Mezinárodní přednášky typu „invited speaker“

Ruth Tachezy

Annual Meeting of the European Cancer Network (ECN), 23.–25. únor, 2006, Budapešť, Maďarsko. Tachezy R. Screening for cervical carcinoma in the Czech republic.

3rd World Congress of International Federation of Head and Neck Oncologic Societies, 27. červen–1. červenec, 2006, Praha. Tachezy R. HPV and head and neck cancer.

7th International Conference on Head and Neck Cancer, San Francisco, USA, 19-23. červenec, 2008. Tachezy R. HPV as a Risk Factor for Head and Neck Cancer.

International Congress on Head and Neck Tumors., 19 – 21. říjen, 2011, Záhřeb, Chorvatsko. Tachezy R. HPV in the etiology of oral and oropharyngeal cancer.

International Workshop on Human Papillomaviruses and Consensus Recommendations for Cervical Cancer Prevention & Colposcopy Training, 18.-21. duben, 2007, Dubrovnik, Chorvatsko. Tachezy R. Quality Assurance of Human Papillomavirus Testing.

EUROGIN 2013, 3. – 6. listopad, 2013, Florencie, Itálie. Tachezy R. Prostate cancer and HPV.

IFHNOS, 21-25. červen, 2023, Řím, Itálie. Tachezy R. Microenvironment of HPV-associated and HPV-negative oropharyngeal tumors

Disertační práce

Název: Diversity of Human Papillomaviruses

Obhájení: 1996

Obor: Molekulární virologie, Přírodovědecká fakulta UK Praha

Účast na řešení grantů, (název a číslo grantu, VZ nebo VC, poskytovatel, roky realizace)

GRANTY:

Hlavní řešitel:

Grantová agentura České republiky

Výzkum diversity papillomavirů u pacientek s cervikálními dysplasiemi v České republice za použití polymerázové řetězové reakce

Doba řešení: 1994 - 1996

Grant: GAČR 312/94/0886

Studium epidemiologie TT viru metodami molekulární biologie

Doba řešení: 2000-2003

Grant: GAČR 310/00/1060

Úloha exprese miRNA u nádorů hlavy a krku asociovaných a neasociovaných s HPV

Úplná strukturovaná bibliografie pro habilitační a jmenovací řízení

Ruth Tachezy

Doba řešení: 2012-2015

Grant: GAČR P304/12/2244

Interní grantová agentura MZ České republiky (Agentura pro zdravotnický výzkum ČR)

Úloha papillomavirů při vzniku nádorových a nenádorových onemocnění mužského urogenitálního traktu

Doba řešení: 2000-2002

Grant: IGA MZd NI6077

HPV vakcíny - předvakační studie (typově specifická prevalence HPV infekcí v České republice)

Doba řešení: 2006 – 2008

Grant: IGA MZd NR8852

Typově specifická prevalence HPV ve screeningové populaci žen

Doba řešení: 2009- 2011

Grant:IGA MZd NC 10 656-3

Prevalence HPV infekcí ve vakcinované populaci žen ČR

Doba řešení: 2011-2014

Grant: IGA MZd NT12372

Stanovení fenotypu a funkce imunitních buněk jakožto prediktorů odpovědi na léčbu u pacientů se spinocelulárním karcinomem hlavy a krku

Doba řešení: 2017-2021

Grant: AZV 17-28255A

Ministerstvo školství a mládeže a tělovýchovy České republiky (MŠMT)

Role aspartyl beta hydroxylázy u nádorů asociovaných a neasociovaných s lidskými papilomaviry

Doba řešení: 2019-2023

Grant Inter-Excellence, podprogram Inter-Action LTAUSA18003

Národní institut virologie a bakteriologie

Doba řešení: 2022-2025

Grant: Program EXCELES, ID: LX22NPO5103, EU – Next Generation EU

Spoluřešitel:

Význam lidských papillomavirů v etiologii a prognóze karcinomu orofaryngu a dutiny ústní

Doba řešení: 2001-2003

Grant IGA MZ NC6441

Ruth Tachezy

HPV infekce u orálního a orofaryngeálního karcinomu – klinický význam a využití serologických parametrů v diagnostice a sledování

Doba řešení: 2004-2006

Grant IGA MZ

Využití virologických markerů v léčbě a prevenci karcinomu orofaryngu a dutiny ústní

Doba řešení: 2007 - 2009

Grant IGA MZd NR9466

Vztah virové etiologie nádorů orofaryngu k úspěšnosti jednotlivých léčebných modalit

Doba řešení: 2011 - 2014

Grant IGA MZd NT12483

Optimalizace diagnosticko-terapeutického managementu kondylomat, prekanceróz a karcinomů vulvy

Doba řešení: 2012 - 2015

Grant IGA MZd NT13167

Centrum nádorové ekologie - výzkum nádorového mikroprostředí v organismu podporujícího růst a šíření nádoru

Doba řešení: 2018-2023

Grant Excelentní výzkum, MŠMT CZ.02.1.01/0.0/0.0/16_019/0000785

Vývoj MULTIOMICS analýzy rizik pesticidů na včely s ohledem na skutečné znečištění a další stresory, 2019-2023, QK - Program aplikovaného výzkumu Ministerstva zemědělství na období 2017-2025, ZEMĚ

Mezinárodní granty

Determination of the potential risk of human papillomavirus polymorphisms in cervical cancer development

Doba řešení: 2000-2001

Grant NATO Collaborative Linkage Grant F818

HPV and other risk factors of oral cavity/ oropharyngeal cancer

Doba řešení: 2001-2004

Grant NIH FIRCA 1R03TW001500-01.

Metagenomic analysis of the virome of the honey bee (*Apis mellifera*) in the Czech Republic

Doba řešení: 2017-2019

Grant: CELSA (Central Europe Leuven Strategic Alliance)

Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in the Czech Republic.

Doba řešení: 2021-2022

Grant: ECDC, HERA, 2021, 004 ECD, 12218

Ruth Tachezy

Delivering a Unified Research Alliance of Biomedical and Public Health Laboratories against Epidemics (DURABLE)

Doba řešení: 2023-2027

Grant: EU4H, EU4H-2021-PJ4, 101102733

Granty ostatní:

Research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. Clinical trial NCT 01375868, EudraCT 2011-002667-14, Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?

RNDr. Ruth Tachezy, Ph.D.